Nanobiotix 2018 Q4 and Annual Revenues - Seite 2

-

-

-

-

Services

3,614

21,816

73,304

-

Other sales

     

6,630

     

-

     

-

     

-

 

Activity and results

In total, Nanobiotix’s revenue for the fourth quarter amounted to €10,244.

Most of the revenue generated by the company during this period came from services that Nanobiotix provided to its partners pursuant to its commercial agreements.

Overall, Nanobiotix’s annual revenue in 2018 amounted to €105,364.

In October 2018, the positive results of phase II/III in Soft Tissue Sarcoma with NBTXR3 were presented at the European Society of Medical Oncology (ESMO) congress. NBTXR3 is the first radiotherapy enhancer to demonstrate clinically meaningful benefits for patients with locally advanced Soft Tissue Sarcoma compared to radiotherapy alone.

Furthermore, on October 16, 2018, Nanobiotix announced that it had received the first tranche disbursement of 16 million euros as a loan from European Investment Bank. Proceeds will be used to toward the development of NBTXR3 clinical trial in the head and neck cancers and will support Nanobiotix’s European go-to-market strategy

2019 Financial agenda

Nanobiotix will announce its financial and operating results as follows:

• March 15, 2019 – 2018 Annual results
• April 11, 2019 – Annual General Meeting, Paris, France
• April 30, 2019 – Revenue for Q1
• July 19, 2019 – Revenue for Q2
• September 4, 2019 - Half year results
• October 25, 2019 – Revenue for Q3

Breakdown of Nanobiotix’s shareholding structure as of December 31, 2018